

AHI Commentary for the Quarter Ended 31 December 2022

Highlights

- **AHI concludes acquisition of wellteq Digital Health Inc.**
- **Scott Montgomery appointed CEO of AHI**
- **AHI changes name to Advanced Health Intelligence Ltd**
- **AHI appoints Jacqueline Yee to the Board of Directors**
- **AHI expands its technology offering**
- **Current partner update**
- **AHI receives \$1,209,334 R&D grant plus \$1,000,000 facility**
- **Clarity on Financial lodgements and compliance**

Advanced Health Intelligence Ltd (ASX:AH1) (NASDAQ:AH1) (formerly known as Advanced Human Imaging Ltd) ('AHI' or 'the Company') is pleased to update shareholders regarding the Appendix 4C and to provide its shareholders with an update on its activities for the quarter ended 31 December 2022, along with the multiple partnerships the Company progressed over the course of 2022.

As released to the ASX on 2 September 2022, AHI entered into a definitive arrangement agreement (the "Arrangement Agreement") with wellteq Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), ("wellteq"), whereby AHI was to acquire all of the outstanding shares of wellteq in an all-share acquisition (the "Transaction").

Pursuant to the terms of the Arrangement Agreement, wellteq shareholders were to receive one (1) ordinary share of AHI (an "AHI Share") for every six (6) wellteq common shares (a "wellteq Share") held (or 0.1667 AHI Shares for every 1 wellteq Share).

AHI were to issue a total of approximately 17,811,508 AHI shares in total consideration for 100% of wellteq's shares. Following the completion of the Transaction, wellteq shareholders in aggregate were to hold approximately 9.573% of AHI's issued capital. For further detail on the terms of the acquisition, please refer to the release outlined.

As announced to the ASX on 7 December 2022, AHI completed the Arrangement Agreement to acquire wellteq.

The Transaction saw AHI acquire wellteq's complementary software assets in the health and wellness space, which are intended to be integrated with AHI's software assets. AHI also consider wellteq's target market to be consistent with its current focus.

Upon conclusion of the Transaction, wellteq nominated two directors to the Board of Directors of AHI. The nominee Directors were Scott Montgomery, CEO and a director of wellteq, and Peter Vaughan, Chair of the

wellteq Board of Directors, Mr. Montgomery was also reported as CEO of AHI. Subsequent to those appointments, AHI welcomed Ms Jacqueline Yee to the Board of AHI, who replaced Dr Peter Vaughan.

AHI announced and completed two material acquisitions during the calendar year 2022, to expand the technology capabilities of AHI and facilitate broader market demand whilst streamlining integration and release timing. AHI has transformed from a body scanning company facilitating the capture of body dimensions and composition assessment into a full-suite risk assessment offering appealing to a greater audience.

Following the completion of the acquisitions of wellteq Digital Health Inc. ("wellteq") and Vertica Health (Pty) Ltd ("Vertica"), the Company also changed its name to Advanced Health Intelligence Ltd on 8 December 2022, to better describing the Company and its ambition. AHI will now deliver scalable health assessment, risk stratification and digital triage to healthcare providers, insurers, employers, and government agencies.

Since 2014, AHI has been delivering Health-tech innovation using smartphones, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, securing its IP and bringing forth the next frontier in digitizing healthcare with a suite of componentized solutions.

AHI has assembled a world-class team of machine learning, AI, and computer vision experts along with medically trained data scientists to develop a comprehensive smartphone-based risk assessment tool culminating in:

- Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates;
- Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk;
- Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates;
- On-device dermatological skin identification with over 588 skin conditions across 133 categories (Inc. Melanoma); and
- Personalised non-therapeutic health coaching to improve daily habits and build health literacy.

Once fully integrated, the combination of AHI, wellteq and Vertica will deliver a biometrically driven triage solution, all accessible on and via a smartphone. With these advanced technologies, AHI will help its partners identify health risks across their consumers, to enable them then to triage their consumers into right-care pathways for proactive health management.

These unique and proprietary capabilities will allow cost-effective health accessibility for any smartphone user, empowering people to take control of their journey to better health outcomes.

AHI will offer this functionality in several partner-friendly ways to increase accessibility, minimise friction and reduce the time to market. The new delivery options available are via white-label applications, URL-based integration, web-based applications, or the traditional Software Development Kit ("SDK") that AHI previously offered.

All of this will assist AHI in not only increasing revenue within current partnerships, but also unlocking multiple partnership approaches AHI has received but had been unable to engage due to the integration requirements.

With the expanded application offering AHI has made to its technology suite via the wellteq and Vertica acquisitions. AHI will be conducting a review of all partnerships over the course of Q1 and Q2 2023. The intention is to demonstrate the new capabilities and the appropriate fit with the partnerships for the technology and AHI's direction.

Current AHI partner's activity and current position

Activate Health OÜ

As per ASX Announcement on 29 August 2022, the Company entered into a Master Services Agreement (“Activate MSA”) with digital health provider Activate Health OÜ (“Activate”).

The parties have executed the standard AHI MSA, which entails the legal and contractual terms in which AHI agrees to grant Activate the right to use AHI’s licensed SDKs for IOS and Android platforms for body circumference measurements, face scan measurements and related intellectual property once integrated into the Activate consumer and digital therapeutics (DTx) platforms.

The Activate MSA incorporates the following information and guidelines: commercial undertakings, SDK, end-user license, technology support, data processing agreement, fee schedule and professional services, including implementation support and training services, which are to be provided by AHI within the agreement with Activate.

The initial term of the Activate MSA is for two years from commencement and will automatically extend for subsequent consecutive periods, each of equivalent length to the initial term. Early termination procedures are included for either party to the Activate MSA.

The pricing mechanism in the Activate MSA is based on either single scans or bulk purchases of scans. Activate purchased a block of 4,000 FaceScans and a block of 4,000 BodyScan’s for EUR€22,960, to be paid in two scheduled payments before the end of 2022. Both payments have been received.

Activate soft launched their app to the Estonian market in September 2022 and continues to promote their app of which a major component is the AHI technology.

Nextmedicall S.A.C

On 24 March 2022, the Company entered into a Master Services Agreement (“Nextmedicall MSA”) with the digital health and medical group NEXTMEDICALL S.A.C (“Nextmedicall”).

The Nextmedicall MSA entails the legal and contractual terms in which AHI agrees to grant Nextmedicall the right to use AHI’s licensed SDKs and related intellectual property once integrated into the Nextmedicall application/platform. The initial term of the MSA is for one year from the commencement date and will automatically extend for subsequent consecutive periods, each of equivalent length to the initial term.

The Nextmedicall MSA incorporates the following information and guidelines, Commercial undertakings, SDK, End User License, Technology Support, and the Data Processing Agreement. At the request of Nextmedicall, AHI also granted Nextmedicall a 180-day non-solicitation and non-compete clause and minor pricing adjustments.

Nextmedicall is currently integrating the AHI MultiScan SDK into the Nextmedicall application and platform. The initial integration will allow access to FaceScan, followed by the proprietary BodyScan, empowering its users with an ability to track and ascertain dimensional base risk assessment and vitals sign.

The financial impact of this MSA on AHI cannot be currently quantified, and there are no minimum order requirements in the agreement.

AHI continues to support Nextmedicall with their FaceScan integration and testing with the proposed launch of FaceScan, as part of NextMedicall’s telehealth platform, to be at the end of Q1 2023. As at the date of this report, AHI’s partnership with NextMedicall has not begun to generate revenue.

Bearn LLC

On 5 April 2020, the Company entered into an agreement (the “Bearn Agreement”) with Bearn LLC (“Bearn”) whereby we granted Bearn a license to our proprietary SDK and access to our BodyScan Platform, with Bearn to integrate our Platform into its own app. The initial term of the Bearn Agreement was 12 months, and it is now auto-renewing for further 12-month periods and will continue to do so unless either party provides at least 90 days’ written notice to the other party prior to the expiry of the current term.

On 9 February 2022, the Bearn Agreement was updated to include the integration of FaceScan into the Bearn Platform. This agreement includes fees consisting of Per Scan Fees for BodyScan (number of body scans captured multiplied by US\$2.00), subscription pricing for FaceScan and BodyScan, Data Storage Fees, Support Fees, Incident Support Fees, Measurement Support Fees and Additional Fees (each as defined in the Bearn Agreement).

On 22 January 2021, the Company entered into a subsequent agreement with Bearn, in which we provided a funding arrangement of US\$500,000 to assist Bearn in expanding and marketing the Bearn Platform. Under the subsequent agreement, Bearn had undertaken to repay the funds within 12 months. AHI has agreed to extend this deadline to 30 June 2023. The funding is secured by the majority holding of Bearn and its technology. Bearn remains committed to delivering AHI with 1,000,000 active monthly users within 12 months of their commercial launch, which is yet to occur. As noted in AHI’s ASX release dated 18 May 2022, Bearn had launched both iOS and Android applications in the US app stores and multiple partner integrations were underway.

Integration over the second half of 2022 with Bearn’s partners has slowed due to funding delays. Aaron Drew, CEO of Bearn, has informed AHI it is in advanced discussions with a funding partner and hopes to have this concluded in Q1 2023.

Bearn continues to offer AHI’s BodyScan and FaceScan, via the Bearn App, which our technology enhances their current solution and ability to provide their end users with an overall Health Score.

Bearn remains highly motivated and engaged to utilise the AHI technology with a number of new and current partners looking to adopt the combined offering in 2023.

Biomorphik

On 15 September 2020, the Company entered into an agreement with Biomorphik PTY Ltd. (“Biomorphik”) whereby we granted a license to our proprietary SDK, and access to our cloud-based anthropometric measurement Platform to Biomorphik. The initial term of the Biomorphik Agreement was 24 months, and the term automatically rolled over into a further 24-month term at the end of the initial term. At the end of this second 24-month term, the Biomorphik Agreement it will auto-renew for a further 24 months unless either party provides at least 90 days’ written notice to the other party prior to the expiry of the current term. This agreement includes fees consisting of User Fees, Monitoring Fees, Data Storage Fees, Support Fees and Additional Fees (each as defined in the Biomorphik Agreement).

Biomorphik CEO Nathaniel Peeks has confirmed with AHI its intention to expand the partnership to include the new health risk assessment capabilities in Q2 2023 once Biomorphik has concluded its funding round, which had been hampered throughout the 2021 and 2022 COVID conditions. As at the date of this report, AHI’s partnership with Biomorphik has not begun to generate revenue.

Jayex Healthcare Ltd

On 28 September 2020, the Company entered into a binding Term Sheet with NuraLogix and Jayex Healthcare Ltd. (“Jayex”), an Australian technology and services company aimed at bringing choice, convenience and efficiency to healthcare professionals, patients and consumers (the “Jayex Terms Sheet”). Under the Jayex Terms Sheet, the parties agreed to collaborate and work together to design, develop and integrate the *CompleteScan* Platform into Jayex’s existing platform. As stated on the Jayex website, the

company currently has over 50,000,000 patient interactions a year across 6,500 healthcare organizations and providers. The Company has not yet begun to generate revenue from this arrangement and no definitive agreement with Jayex has been finalized. The companies have remained in communication and intend to progress the partnership in 2023.

The Original Fit Factory (TV.Fit)

On 21 April 2021, AHI concluded all definitive agreements (“Agreement”) with The Original Fit Factory (“TOFF”), which has developed the world-leading TRUCONNECT and TV.FIT fitness and well-being platforms are available through iOS and Android app stores across 71 countries. TOFF have both B2C and B2B solutions. Our *BodyScan* technology has been integrated into TOFF’s B2C and B2B offerings. The initial term of this Agreement is 24 months, and it will auto-renew for a further 24 months unless either party provides at least 90 days written notice to the other party prior to the expiry of the current term. The Agreement includes commercial terms, SDK End User License Agreement, Data Processing Agreement and Support Agreement. The application launched on 8 May 2021.

TOFF continue to offer AHI’s *BodyScan* technology to their end users as a PAYG.

TOFF has appointed a new General Manager (“GM”) within the organization, AHI will be meeting with TOFF and the new GM in Q1 2023 to showcase the new *BodyScan* capture process and hand over to the Customer Team to assist in increasing revenue. AHI intends to showcase the new functionality that TOFF have not seen to grow the offering further opportunities between the parties. As at the date of this report, AHI’s partnership with TOFF has not begun to generate revenue.

Inter-PSY B.V

On 7 February 2022, the Company entered into a Master Services Agreement with INTER-PSY B.V (“Inter-Psy MSA”). Inter-Psy B.V (“Inter-Psy”) is a Netherlands-based mental health and preventative care company that has developed HEALTHiCHECK, a preventative health screening app for the Dutch and European markets.

The Inter-Psy MSA entails the legal and contractual terms in which AHI agrees to grant Inter-Psy the right to use AHI’s licensed SDKs and related intellectual property once integrated into the Inter-Psy application/platform. The initial term of this Agreement is 12 months, and it will auto-renew for a further 12 months unless either party provides at least 30 days’ written notice to the other party prior to the expiry of the current term.

The Inter-Psy MSA incorporates the following information and guidelines: commercial undertakings, SDK, end-user license, technology support, data processing agreement, fee schedule and professional services, including implementation support and training services, which are to be provided by AHI within the Inter-Psy MSA.

Due to various internal Inter-Psy delays, the integration of the AHI MultiScan SDK (software development kit) into the Inter-Psy application was hindered for the better part of 2022. The integration into the Inter-Psy platform recommenced towards the end of 2022 and is now continuing with a view to be finalized in Q2 of 2023.

CustIntCo Pte Ltd

As per ASX Announcement on 5 April 2022, the Company entered into a Master Services Agreement (“CustIntCo MSA”) with Singapore-based digital health and financial intelligence platform CustIntCo Pte Ltd. (“CustIntCo”).

The parties have executed the standard AHI MSA, which entails the legal and contractual terms in which AHI agrees to grant BizBaz (a wholly owned subsidiary of CustIntCo), the right to use AHI’s licensed SDKs for IOS and Android platforms for body circumference measurements face scan measurements and related intellectual property once integrated into the BizBaz application/platform.

The CustIntCo MSA incorporates the following information and guidelines: commercial undertakings, SDK, end user license, technology support, data processing agreement, fee schedule and professional services, including implementation support and training services, which are to be provided by AHI within the CustIntCo MSA.

The initial term of the CustIntCo MSA is for one year from commencement and will automatically extend for subsequent consecutive periods, each of equivalent length to the initial term. Early termination procedures are included for either party to the CustIntCo MSA.

The financial impact of the CustIntCo MSA on AHI cannot be currently quantified, and there are no minimum order requirements contained in the agreement.

Delays due to internal CustIntCo staff turnover, the integration has experienced delays. AHI is working with CustIntCo to assist in integrating the web-based FaceScan SDK as a first step. As at the date of this report, AHI's partnership with CustIntCo has not begun to generate revenue.

MVMNT

As previously updated to the ASX, AHI has entered into a suite of definitive agreements with MVMNT (MVMNT Definitive Agreements). The MVMNT Definitive Agreements replaced the previous binding Terms Sheet. The MVMNT Definitive Agreements remain on foot and govern the continuing relationship between the parties. MVMNT represents a number of health and fitness-based businesses, sporting identities, products and platforms.

The partnership experienced delay primarily due to MVMNT moving all of its platforms and applications to a single code base, for better, smoother integrations across the company's multiple partnerships. AHI board member Mike Melby is a founder of MVMNT and continues to support the long-term integration of the AHI technology into the MVMNT platforms and applications.

Nexus Vita Pte Ltd

The long-awaited integration of the AHI technology into the Nexus-Vita application has been completed by AHI and external development house BlueSky Digital Labs. The application has been released to Nexus-Vita for their approval and final sign-off. The parties hope to have all clearances from Nexus-Vita no later than the end of Q1 2023. As noted in AHI's Quarterly Activities Report for the June 2022 quarter (released on 29 July 2022), integration of AHI's technology into the Nexus-Vita application experienced delays in the June quarter due to scope creep and additional functionality requests by Nexus-Vita. These delays continued into Q3 2022.

As stated, the application integration has been completed and handed over to Nexus-Vita for final QA and sign-off. Once the technology integration has been signed off by Nexus-Vita, the parties will conclude the associated Master Services Agreement, which will govern the timing and commercial outlines for launch. AHI will provide a further update to the market once these processes are complete.

Tinjoy Biotech Limited Agreement

The AHI technology integration into the Tinjoy-owned Health Cube application has been completed and is awaiting a formal launch by Tinjoy into the audience Tinjoy has access to across the multiple partnerships and businesses Tinjoy works with throughout China. The companies experienced rolling delays throughout 2022 due to the Zero-COVID policies implemented by the government. Pleasingly these restrictions have been lifted. Tinjoy has informed AHI that business is slowly progressing back to normal. Tinjoy hopes its operations will be fully functioning in Q2 2023, enabling sufficient staff to return to the marketing and call centre.

As previously reported, COVID-related restrictions had affected Tinjoy's ability to perform the services contemplated under the Tinjoy Marketing Agreement. As such, AHI's contribution to the rollout and

marketing of the Health Cube app of US\$50,000 to Tinjoy remains outstanding until these services can be provided.

The leadership at Tinjoy remain great supporters of the AHI technology and the functionality it provides. Tinjoy have reaffirmed how important the relationship between the companies is, and will continue to be, as is the value in the AHI scan capabilities embedded in the Health Cube app. As at the date of this report, AHI's partnership with Tinjoy has not begun to generate revenue.

Cubert Inc

As disclosed in AHI's Quarterly Activities Report for the June 2022 quarter (released on 29 July 2022), Cubert has experienced delays in its integration timelines. AHI is currently communicating with Cubert to see how the parties can progress the partnership to a successful integration and launch of the integrated app. AHI has no further updates with respect to the integration process at this time but will continue to comply with its continuous disclosure obligations and update the market should any progress be made or if any material change occurs.

Cubert has not shared commercially sensitive information with respect to its users with AHI outside of the initial numbers provided in previous ASX announcements.

As far as AHI is aware, both parties remain committed to integrating AHI's technology into the FitTrack My Health app. Should this change, AHI will update the market accordingly.

Additional events and matters.

Throughout the quarter AHI released a number of announcements to shareholders keeping them apprised of events across the ASX and NASDAQ, which the board felt further clarity should be provided to assure shareholders it is on top of events and requirements pertaining to the compliance required to maintain its ASX and NASDAQ listings.

As released on 30 September 2022, AHI updated shareholders on the delay it encountered lodging its June 30 Financial statements. As outlined, the delay allowed the newly appointed company auditors PKF Brisbane additional time to conclude the needed reviews of the financial statements and increased audit requirements needed for its NASDAQ compliance. The position was rectified by 13 October 2022.

AHI has broadened the finance team to avoid such delays moving forward.

As released to the ASX on 23 November 2022, AHI received a deficiency notice from the NASDAQ listing Qualification Staff regarding the late filings of the company's 20-F end-of-year annual report. The company was unable to meet the timing of the lodgement as it was required by its auditors to provide further information pertaining to its investment into Triage Technology Inc. AHI was required to engage an independent valuer to value the Triage investment which required further time to conclude and enter into the Annual report and will form part of the new filings to be lodged in the 20-F. All of these matters were concluded as fast as practically possible. Unfortunately, this delay saw the festive season commence, and the company's US audit team did not return to the office until 16 January 2023. The team has immediately commenced its process, and AHI has provided all information and hopes to lodge the 20-F before the close of business on Friday, 3 February 2023.

As released to the ASX on 22 December 2022, AHI was granted a 180 day extension from the NASDAQ listing Qualification Staff regarding its bid price compliance. Like most listed companies, the company's share price experienced selling pressure over the course of 2022, seeing the share price trade under USD\$1.00 for 30 trading days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the bid price for the Company's common stock must close at \$1.00 per share or more for a minimum of 10 consecutive business days to comply with the rules as set out.

The Company has a number of options available to it. These options are to trade above USD\$1.00 as required, seek approval to reconstruct the shares in the company to meet the minimum USD\$1.00 requirement or to delist from NASDAQ. The Company has until the 19 June 2023 to comply and is doing

all things practically possible to meet the requirement and maintain its good standing with NASDAQ and compliance rules.

Importantly, Nasdaq's written notice does not affect the listing or trading of the Company's common stock at this time, and the Company will continue evaluating its alternatives to resolve this listing deficiency.

As released to the ASX on 1 December 2022, AHI appointed Mr Montgomery to the Board as the Company's new Chief Executive Officer and Managing Director. Mr Montgomery has over 20-years of experience in enterprise healthcare around the world, with 15 of those as a founder or director of public and private companies. Mr Montgomery successfully exited two previous Health companies he had founded and is a welcome addition to the AHI team.

Subsequent events of note

As released to the ASX on 25 January 2023, AHI had concluded formal agreements with Upvio Healthtech.

Upvio offers medical, health and wellness practices powerful technology, including human imaging, feature-rich appointment scheduling, digital forms, video calls, virtual waiting rooms, asynchronous and synchronous chat, a patient portal, and the ability to integrate into any existing software. Upvio enables geo-cloud storage for securely storing sensitive patient information, ensuring that patients' data is always kept safe and secure. Upvio aims to be the first telehealth platform in the world with in-built contactless human imaging tools that can provide a scientifically validated health risk assessment in real-time. This is a game-changing development, as it means that healthcare professionals can now obtain an accurate picture of a patient's health and risk status more easily, conveniently and affordably without the need for physical contact, drastically reducing the risk of malpractice. The platform is built on a digital-first ethos, with both patients and healthcare professionals in mind and brings together the best-of-breed technologies, including AHI's scanning and risk assessment capabilities.

As released to the ASX on 30 January 2023, AHI was pleased to inform shareholders the Company was to receive an R&D payment of \$1,209,334 from the Australian Tax Office. Pleasingly the funds have now been received. In addition to the R&D funding payment, AHI had secured an additional \$1,000,000 short term loan facility to bolster its cash position further. AHI is currently negotiating funding offers it has received from a number of parties. The facility, along with the R&D reimbursement received gives AHI ample time to evaluate and finalise funding offers it has received. AHI will keep shareholders informed as this progresses.

Cash at Bank at 31 December 2022

As reported on the attached Appendix 4C, the Company has a closing cash balance of \$553,719. The Company's future funding is addressed in the paragraph above.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ADVANCED HEALTH INTELLIGENCE LTD

ABN

85 602 111 115

Quarter ended ("current quarter")

31 DECEMBER 2022

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	110	169
1.2 Payments for		
(a) research and development		
(b) product manufacturing and operating costs		
(c) advertising and marketing	(85)	(198)
(d) leased assets		
(e) staff costs	(985)	(1870)
(f) administration and corporate costs	(916)	(1991)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(1876)	(3890)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	(187)
(b) businesses		
(c) property, plant and equipment	(4)	(6)
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities	(956)	(1516)
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material) ¹	321	321
2.6	Net cash from / (used in) investing activities	(639)	(1388)
	1 – Wellteq cash at bank at 6 December 2022		

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(178)	(178)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	(178)	(178)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	3248	6011
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1876)	(3890)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(639)	(1388)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(178)	(178)
4.5	Effect of movement in exchange rates on cash held	(1)	(1)
4.6	Cash and cash equivalents at end of period	554	554

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	554	554
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	554	554

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(9) ²
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

2 – The related party payment refers to the director's fees paid to our Non-executive Chairman, Mr Nicholas Prosser.

Quarterly cash flow report for entities subject to Listing Rule 4.7B


7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1	Loan facilities	
7.2	Credit standby arrangements	
7.3	Other (please specify)	
7.4	Total financing facilities	0
7.5	Unused financing facilities available at quarter end	0
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8. Estimated cash available for future operating activities	\$A'000	
8.1	Net cash from / (used in) operating activities (item 1.9)	(1877)
8.2	Cash and cash equivalents at quarter end (item 4.6)	554
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (item 8.2 + item 8.3)	554
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.29
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: The company does expect to have the current level of net operating cash flows for the time being. The funding shortfall is addressed on the page 8 of the attached commentary on the quarter ended 31 December 2022		
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: Yes, it has. Refer to the answer 8.6.1 above.		
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: Yes, it does through further capital raising, with several financing offers received.		
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: ...31 January 2023.....

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.